Day: January 3, 2024

BOCA RATON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) — NewtekOne, Inc. (the “Company” or “NewtekOne”) (NASDAQ: NEWT), announced today that its nationally chartered bank subsidiary, Newtek Bank, N.A., closed a record $262.9 million of SBA 7(a) loans for the three months ended December 31, 2023, which represents a new quarterly record for the Company, and a 20.6% increase over the previous quarterly record of $218.0 million SBA 7(a) loans closed for the three months ended September 30, 2023. In addition, NewtekOne, through Newtek Small Business Finance and Newtek Bank, closed a record $828.1 million of SBA 7(a) loans for the twelve months ended December 31, 2023, a new annual record for the Company, and a 7.3% increase over $771.9 million of SBA 7(a) loans closed for the twelve months ended December 31, 2022. Newtek Bank currently expects...

VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024. Company Presentation Details:Date: Monday, January 8, 2024   Time: 9-9:40 AM Pacific Time (12-12:40 PM Eastern Time)   Presenter: Ian Mortimer, President and Chief Executive Officer, Xenon Pharmaceuticals   A live audio webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage...

Scorpius subsidiary to manufacture novel biologic targeting substance use disorder DURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius BioManufacturing subsidiary (“Scorpius”) has commenced work on a contract that it was awarded by a leading university to develop and manufacture a novel biologic targeting substance use disorder, which includes drug, alcohol and opioid addiction. Jeff Wolf, CEO of NightHawk, commented, “We are honored to have been awarded this multi-million dollar contract by one of the foremost research universities in the United States. Scorpius was selected due to its process development and large molecule manufacturing expertise, as well...

Additional Ewing Sarcoma Patient in Company’s Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and Cyclophosphamide Reaches 60% HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer Center (MDACC or MD Anderson) is now listed as active and recruiting on clinical trials.gov – trial NCT04734990. Salarius also announces that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide (TC) has achieved a partial response as demonstrated by at least a 30% decrease in the sum of diameters of the patient’s target lesions, bringing the objective response...

Safe & Green Holdings’ Modular Manufacturing FacilitySafe & Green Holdings’ Modular Manufacturing FacilitySafe & Green Holdings’ Modular Manufacturing FacilityMIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) — Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures for residential, commercial, and point-of-care medicine, today provided the following letter to stockholders from Paul Galvin, the Company’s Chairperson and CEO:Dear Stockholders, We are pleased to share with you the significant milestones and exciting developments that Safe & Green Holdings accomplished in 2023 as well as take a look at what we believe is a very promising future for the Company in 2024. 2023 Highlights:Completed the...

Revenue: * $14.3M for Q4/2023, 18% over Q4/2022* $56.2M for FY 2023, 29% over FY 2022 Announces Management Changes as Part of the “Reshaping Nano” Campaign to Drive Profitability Waltham, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printing solutions, today announced its financial results, on a preliminary basis, for the fourth quarter and twelve months ended December 31st, 2023. In conjunction with its unaudited preliminary results, Nano Dimension added comments from the CEO on the Reshaping Nano Initiative (the “Initiative”), the year ahead, and the announcement of senior leadership team changes. Record...